Survodutide

(BI 456906) Dual GLP-1/Glucagon Receptor Agonist Survodutide is a synthetic 29-amino acid peptide designed as a dual agonist of glucagon-like peptide-1 receptor (GLP-1R) and glucagon receptor (GCGR). Engineered with a C18 fatty diacid chain for albumin binding, it achieves an extended half-life of 109–115 hours, allowing convenient onceweekly subcutaneous administration. The peptide demonstrates preferential GLP-1R activation (~8:1 ratio GLP-1R:GCGR) to maximi z e metabolic benefits while minimi z ing potential glucagonrelated adverse e ff ects. Mechanism of Action GLP-1R activation - Enhances glucosedependent insulin secretion, suppresses postprandial glucagon, delays gastric emptying, and reduces appetite through central hypothalamic pathways. GCGR activation - Increases energy expenditure via hepatic fatty acid oxidation, thermogenesis, and lipolysis; elevates FGF21 and hepatic NNMT as metabolic biomarkers. Dual pathway synergy - Combines reduced energy intake with increased energy expenditure to optimi z e weight loss and glycemic control.